Top
Gene Therapy Vehicle for Sickle-Cell Disease Shifts Forward - Healing Genes
2736
post-template-default,single,single-post,postid-2736,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

Gene Therapy Vehicle for Sickle-Cell Disease Shifts Forward

Share on facebook
Share on google
Share on twitter
Share on linkedin

A radically redesigned viral vector may improve the delivery of therapeutic genes to patients with sickle-cell disease. According to tests in animal models, the new vector is up to ten times more efficient at incorporating corrective genes into bone marrow stem cells than conventional vectors, and it has a carrying capacity that is up to six times higher.

The conventional vectors that have been used to deliver gene therapies for sickle-cell disease have a reverse structural orientation. This orientation, which obliges the viral vector-making machinery to read the therapeutic genes in reverse, results in viral titers and transduction efficiencies lower than those that could be achieved with a forward orientation. For decades, the drawbacks of the reverse orientation were accepted because it was a convenient way to prevent a persistent problem attributed to RNA splicing.

Basically, treating sickle-cell disease with gene therapy requires that the delivery vector’s various components include intron 2. It is required for high-level expression of another key component, the β-globin gene. Intron 2, however, gets “clipped out” during the normal vector preparation process if it is left in the natural, forward direction.

To move the delivery of the β-globin gene forward—in both senses, researchers based at the National Institutes of Health (NIH) have been working on a unique workaround. John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute (NHLBI), has led an effort to create a viral vector that leaves intron 2 intact but also incorporates a new forward-oriented β-globin vector.

In contrast to the old vector, the gene sequence, or “message,” of the new β-globin vector is read forward, making the gene translation approach less complicated.

“Our new vector is an important breakthrough in the field of gene therapy for sickle cell disease,” said Tisdale. “It’s the new kid on the block and represents a substantial improvement in our ability to produce high-capacity, high-efficiency vectors for treating this devastating disorder.”

Read the full story here: https://www.genengnews.com/news/gene-therapy-vehicle-for-sickle-cell-disease-shifts-forward/

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.